Search results for "Advanced glycation end products."

showing 5 items of 15 documents

Decreased plasma soluble RAGE in patients with hypercholesterolemia: Effects of statins

2007

The receptor for advanced glycation endproducts (RAGE) is overexpressed at sites of vascular pathology. A soluble RAGE isoform (sRAGE) neutralizes the ligand-mediated damage by acting as a decoy. We hypothesized that in hypercholesterolemia up-regulation of the ligand-RAGE axis may bridge impairment of nitric oxide biosynthesis with oxidative stress. We measured in 60 hypercholesterolemic patients and 20 controls plasma total sRAGE levels, urinary 8-iso-prostaglandin (PG) F(2alpha) excretion, and plasma levels of asymmetric dimethylarginine (ADMA). The effects of two structurally different statins (pravastatin and atorvastatin) on these parameters were analyzed in 20 hypercholesterolemic su…

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaStatinmedicine.drug_classAtorvastatinHypercholesterolemiaReceptor for Advanced Glycation End ProductsFree radicalsArginineDinoprostNitric Oxidemedicine.disease_causeBiochemistrychemistry.chemical_compoundDouble-Blind MethodPhysiology (medical)Internal medicineHyperlipidemiaAtorvastatinmedicineHumansPyrrolesReceptors ImmunologicEndothelial dysfunctionPravastatinChemistryVascular diseaseAnticholesteremic AgentsStatinnutritional and metabolic diseasesMiddle AgedAtherosclerosismedicine.diseaseADMACross-Sectional StudiesHyperlipidemiaEndocrinologyHeptanoic AcidsOxidative streFemalelipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsNitric Oxide SynthaseAsymmetric dimethylarginineOxidative stressPravastatinsRAGEmedicine.drugFree Radical Biology and Medicine
researchProduct

Genome-wide association study identifies five loci associated with lung function

2009

Pulmonary function measures are heritable traits that predict morbidity and mortality and define chronic obstructive pulmonary disease (COPD). We tested genome-wide association with forced expiratory volume in 1 s (FEV(1)) and the ratio of FEV(1) to forced vital capacity (FVC) in the SpiroMeta consortium (n = 20,288 individuals of European ancestry). We conducted a meta-analysis of top signals with data from direct genotyping (n < or = 32,184 additional individuals) and in silico summary association data from the CHARGE Consortium (n = 21,209) and the Health 2000 survey (n < or = 883). We confirmed the reported locus at 4q31 and identified associations with FEV(1) or FEV(1)/FVC and co…

OncologySpirometryMalemedicine.medical_specialtyVital capacityPopulationReceptor for Advanced Glycation End ProductsVital CapacityGenome-wide association studyBiologyPolymorphism Single NucleotideArticlePulmonary function testing03 medical and health sciencesFEV1/FVC ratioPulmonary Disease Chronic Obstructive0302 clinical medicineMeta-Analysis as TopicInternal medicineTensinsForced Expiratory VolumeGeneticsmedicineHumansRNA MessengerReceptors ImmunologiceducationLung030304 developmental biologyGlutathione Transferase0303 health scienceseducation.field_of_studyCOPDmedicine.diagnostic_testGenome HumanGene Expression ProfilingMicrofilament Proteinsrespiratory systemmedicine.disease3. Good healthRespiratory Function Tests030228 respiratory systemSpirometryImmunologyFemaleReceptors Serotonin 5-HT4Hedgehog interacting proteinThrombospondinsGenome-Wide Association Study
researchProduct

Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases.

2008

The receptor for advanced glycation end products (RAGE) is a 55-kDa type I membrane glycoprotein of the immunoglobulin superfamily. Ligand-induced up-regulation of RAGE is involved in various pathophysiological processes, including late diabetic complications and Alzheimer disease. Application of recombinant soluble RAGE has been shown to block RAGE-mediated pathophysiological conditions. After expression of full-length RAGE in HEK cells we identified a 48-kDa soluble RAGE form (sRAGE) in the culture medium. This variant of RAGE is smaller than a 51-kDa soluble version derived from alternative splicing. The release of sRAGE can be induced by the phorbol ester PMA and the calcium ionophore c…

endocrine system diseasesADAM10Receptor for Advanced Glycation End ProductsMatrix Metalloproteinase InhibitorsHydroxamic AcidsBiochemistryProtein biotinylationCell LineDiabetes ComplicationsADAM10 ProteinGlycationAlzheimer DiseaseHumansProtein IsoformsProtease Inhibitorscardiovascular diseasesRNA Small InterferingReceptors ImmunologicReceptorMolecular BiologyProtein kinase CCalcimycinIonophoresChemistryHEK 293 cellsCell Membranenutritional and metabolic diseasesMembrane ProteinsCell BiologyProtein Structure TertiaryADAM ProteinsAlternative SplicingEctodomainBiochemistryMatrix Metalloproteinase 9cardiovascular systemCarcinogensImmunoglobulin superfamilyTetradecanoylphorbol AcetateAmyloid Precursor Protein Secretaseshuman activitiesThe Journal of biological chemistry
researchProduct

Statins stimulate the production of a soluble form of the receptor for advanced glycation end products

2013

The beneficial effects of statin therapy in the reduction of cardiovascular pathogenesis, atherosclerosis, and diabetic complications are well known. The receptor for advanced glycation end products (RAGE) plays an important role in the progression of these diseases. In contrast, soluble forms of RAGE act as decoys for RAGE ligands and may prevent the development of RAGE-mediated disorders. Soluble forms of RAGE are either produced by alternative splicing [endogenous secretory RAGE (esRAGE)] or by proteolytic shedding mediated by metalloproteinases [shed RAGE (sRAGE)]. Therefore we analyzed whether statins influence the production of soluble RAGE. Lovastatin treatment of either mouse alveol…

medicine.medical_specialtyendocrine system diseasesADAM10Receptor for Advanced Glycation End ProductsBeta-CyclodextrinsQD415-436PharmacologyBiochemistryCell LineRAGE (receptor)MiceEndocrinologyGlycationInternal medicinediabetic complicationsmedicineAnimalsHumansSecretionLovastatincardiovascular diseasesReceptors ImmunologicReceptorResearch ArticlesDose-Response Relationship DrughypercholesterolemiaChemistrybeta-CyclodextrinsHEK 293 cellsTricarboxylic Acidsnutritional and metabolic diseasesCell BiologyBridged Bicyclo Compounds HeterocyclicADAM 10CholesterolFarnesyl-Diphosphate FarnesyltransferaseEndocrinologySolubilitycardiovascular systemLovastatinHydroxymethylglutaryl-CoA Reductase Inhibitorsatherosclerosishuman activitiesmedicine.drugJournal of Lipid Research
researchProduct

Regulated Proteolysis of RAGE and AβPP as Possible Link Between Type 2 Diabetes Mellitus and Alzheimer's Disease

2009

Epidemiological studies have linked type 2 diabetes mellitus (T2DM) with an increased risk of developing Alzheimer's disease (AD). In T2DM, the elevated blood glucose level promotes formation of advanced glycation end products (AGEs). The receptor for AGEs (RAGE) is a type I membrane-protein and is also able to import amyloid-beta (Abeta) from the blood across the blood-brain-barrier into the brain. Oligomeric Abeta peptides disturb synaptic function in the brain and are believed to contribute to the development of AD. Abeta peptides are released from the amyloid-beta protein precursor (AbetaPP) after sequential proteolysis by beta- and gamma-secretases but alpha-secretase-mediated cleavage…

medicine.medical_specialtyendocrine system diseasesProteolysisReceptor for Advanced Glycation End ProductsAmyloid beta-Protein PrecursorAlzheimer DiseaseGlycationInternal medicinemental disordersmedicineAnimalsHumansReceptors ImmunologicProtein precursorProtein kinase AReceptorAmyloid beta-Peptidesmedicine.diagnostic_testChemistryGeneral Neurosciencenutritional and metabolic diseasesGeneral MedicinePsychiatry and Mental healthClinical PsychologyCholesterolEndocrinologyDiabetes Mellitus Type 2EctodomainPeptide transportAmyloid Precursor Protein SecretasesGeriatrics and GerontologySignal transductionJournal of Alzheimer's Disease
researchProduct